Participated · Series C · Apr 2021

Halodoc is a Jakarta, Indonesia-based digital healthcare ecosystem platform that delivers an all-in-one application covering preventive to curative services. Led by CEO & co-founder Jonathan Sudharta, the company offers services including Home Lab (at-home health tests) and My Insurance (cashless outpatient access integrated with insurers). Halodoc focuses on health communication, education, and information to raise digital health literacy in Indonesia. The company works with the government to accelerate healthcare technology and telehealth regulation under the Ministry of Health. Halodoc said it will use the funds to expand operations, broaden its business reach, and widen its range of services. Early backers include Acrew Capital, Argor (previously Go-Ventures), Allianz X, Bangkok Bank, the Bill & Melinda Gates Foundation, HEAL Partners, Intudo Ventures and others. Halodoc operates a mobile app and website that enable live consultations with more than 20,000 licensed doctors across Indonesia. The platform launched an appointment service in 2020 that connects over 2,000 providers to patients in more than 180 cities. Its Health Store partners with 4,000+ pharmacies to deliver supplements, prescription drugs and other items; Chat with Doctor supports voice, video and chat interactions; and Appointment covers 1,000+ partner hospitals plus COVID-19 testing and vaccination scheduling. Founded in 2016 and led by CEO Jonathan Sudartha, Halodoc aims to deepen its penetration in key healthcare verticals across Indonesia. The company recently completed a new financing round which it plans to deploy toward expanding services and provider reach. The article does not disclose revenue or user counts beyond the provider and partner metrics noted above. Halodoc is an Indonesian healthtech platform offering online consultations with over 20,000 licensed doctors, prescription delivery, and lab test bookings. Founded in 2016, the standalone app also links with Go-Jek's Go-Med feature and uses Go-Jek drivers for medicine deliveries. The platform has collaborated with more than 1,400 hospitals and health service providers and integrates insurance services for hospital visits. Halodoc reports 2 million monthly active users, over 80% of whom are located outside Java, and its user numbers increased 25-fold in a 12-month period in 2018. The company raised IDR 920 billion (US$65 million) in a Series B led by UOB Venture Management to develop services and expand partnerships with health service and insurance providers. Management says the investment will accelerate development of its digital platform to increase access and convenience for millions of users in Indonesia. HaloDoc is Indonesia's first online healthcare application. The company operates an app-based platform delivering healthcare services in Indonesia. It announced it has secured a $13 million Series A funding round. The Series A was led by Clermont Group, a Singapore-based private investment firm. The article's headline also cites participation from Go-Jek and other unnamed investors. The article does not disclose operating metrics, future plans, or additional financial details.

Participated · Series A · Mar 2021

Ajaib is an Indonesian investment app focused on making stock investing accessible to first-time and millennial investors through low-fee trading and mutual funds. Founded in 2019 by Anderson Sumarli and Yada Piyajomkwan, the company says it runs the fourth largest stock brokerage in Indonesia by number of trades. Ajaib announced a $25 million first closing of its Series A in January and has now extended that round. The extension added $65 million, bringing the Series A total to $90 million. The new capital will be used to expand product development and engineering capabilities. Ajaib competes with other local investment apps such as Pluang, Bibit and Bareksa as retail stock ownership in Indonesia grows. Ajaib Group is a mobile-first investment platform launched in 2019 that targets millennials and first-time investors with low-fee stock trading and mutual funds. Its product suite includes Ajaib Sekuritas for stock trading and Ajaib Reksadana for mutual funds, with in-app education, a community feature, and no minimums to open an account. The company claims one million monthly users and says Ajaib Sekuritas became the fifth-largest stock brokerage in Indonesia by number of trades seven months after launching in June 2020. Founders Anderson Sumarli and Yada Piyajomkwan built the app to simplify investing and encourage small, repeat investments. Ajaib has raised a total of $27 million to date, including a $2 million seed in 2019 and the newly announced $25 million Series A. Near-term plans include an educational campaign with the government (#MentorInvestai), expanding tech infrastructure and products, hiring engineers, and focusing on deeper penetration in Indonesia while keeping open regional expansion. Ajaib is an online investment platform that launched earlier this month to offer easy access to personal investments for Indonesians, with a focus on younger users. The platform offers mutual fund products covering stocks, fixed income, and money market instruments and provides investment advice via a mobile application that lets users invest and adjust contributions. Ajaib says it combines financial experts with technology-enabled analysis and is registered with Indonesia’s Financial Services Authority (OJK); it also partners with banks and fund managers. The two co-founders have backgrounds in financial consulting and analysis—CEO Anderson Sumarli previously worked as a data expert at IBM, and CMO/co-founder Yada Piyajomkwan was a consultant at McKinsey—and they entered Y Combinator’s incubation programme in 2018 before establishing Ajaib. The company raised US$2.1M in a seed round and intends to use the funding to improve its platform and build an investment solution tailored to customers’ needs. Ajaib positions itself to serve beginner investors who generally have limited time, funds, and investment knowledge and aims to encourage earlier investment among Indonesia’s middle class.

Participated · Series B · Oct 2015

Humacyte is a Durham, N.C.-based clinical-stage biotechnology platform developing and manufacturing acellular human tissues, including Human Acellular Vessels (HAVs). Its HAV portfolio is in late-stage clinical trials targeting arteriovenous access for hemodialysis, vascular trauma repair, and peripheral arterial disease. The company is also pursuing preclinical programs in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and other cell and tissue applications. Humacyte intends to use recent financing to strengthen financial and operational flexibility as it advances its pipeline and prepares for near-term Phase 3 data readouts. Leadership has stated an objective to prepare the company to become publicly traded. The company announced a definitive business combination agreement with Alpha Healthcare Acquisition Corp. alongside a fully committed $175 million PIPE financing agreement. Humacyte develops technology to grow stable, off-the-shelf investigational human tissue replacements for use in regenerative medicine and vascular and non-vascular surgery. Its lead product, human acellular vessels (HAV), is intended to reduce inflammation and clotting, elicit a low immune response and potentially lower healthcare costs by reducing surgical interventions. The company is running a Phase 2 vascular trauma trial to study HAV for traumatic vascular injuries. In October 2017 Humacyte received a $3.4M contract from the U.S. Department of Defense to fund that trial, and in September 2017 it was awarded $14.1M from the California Institute for Regenerative Medicine to expand clinical applications of HAV. The company filed with the SEC disclosing a $75M equity raise from 29 investors and did not disclose planned use of the proceeds. Humacyte is led by chairman and CEO Carrie Cox, who joined the company in 2010 and previously served as EVP and then president of Global Pharmaceuticals. Humacyte develops HUMACYL (Human Acellular Vessel/HAV) using a proprietary platform to engineer human extracellular matrix–based tissues that can be shaped into tubes, sheets, or particulates for clinical use. Its lead program is HUMACYL as a vascular access conduit for patients requiring hemodialysis; the company is conducting a pivotal Phase III trial (HUMANITY) comparing HAV to sPTFE grafts and received RMAT designation in March 2017. Humacyte plans broader indications for HUMACYL and is running a new CIRM‑funded study comparing HAV to arteriovenous fistulas in ESRD patients who are candidates for fistulas. The company will monitor evaluable subjects for 24 months in the new study and aims to show HUMACYL is a durable, safe alternative to synthetic grafts and fistulas. Humacyte also investigates HAV for lower extremity arterial bypass in peripheral arterial disease and continues to advance future pipeline products for vascular repair and replacement. Humacyte develops human extracellular matrix–based tissues, including an investigational human acellular vessel (HAV) called HUMACYL, intended to provide vascular access for End Stage Renal Disease patients who require hemodialysis. The company’s platform engineers off-the-shelf tissue products that can be shaped into tubes, sheets, or particulate conformations with properties similar to native tissues. HUMACYL has received FDA Fast Track designation for vascular access and is in ongoing Phase II trials in the U.S. and EU; the company plans to initiate a global Phase III study in the coming months. Humacyte says implanted HAVs have the potential to resemble patients’ own blood vessels and to last longer with fewer complications than current synthetic products. The recent financing will fund the upcoming global Phase III trials and support development of future pipeline products for vascular and non-vascular indications such as coronary artery bypass, trachea and esophagus replacement, and peripheral arterial disease bypass. The company was founded in 2004 and is based in Research Triangle Park, N.C. Humacyte develops a proprietary platform to engineer human tissues that can be formed into tubes, sheets or other shapes to treat vascular diseases and repair the body. The company was founded by Dr. Laura Niklason in late 2004 and is based in Durham, North Carolina. Its lead work centers on creating artificial blood vessels suitable for transplantation into patients such as those with kidney failure. Humacyte is transitioning from development toward commercialization and recently appointed Carrie Cox as CEO to lead that effort. Financially, the company disclosed a $12 million investment via a debt offering from a single investor in an amended SEC filing and previously raised about $7 million in debt about a year earlier. The founder indicated the company has taken in funds from its existing investors to support ongoing work.